Menopause Hormone Therapy in 2026: What the New Label and the New Dementia Data Actually Say

Educational content, not medical advice. Talk with your physician before starting, changing or stopping any hormone treatment.

The FDA softened its boxed warnings in February. A large meta-analysis says hormone therapy neither raises nor lowers dementia risk. Here is how to read both.

Key takeaways

• In February 2026 the FDA approved label changes for six menopausal hormone therapy (MHT) products. The boxed-warning statements on cardiovascular disease, breast cancer and probable dementia were removed from those labels.
• A December 2025 systematic review and meta-analysis in The Lancet Healthy Longevity (about 1 million women, 10 studies) found no significant link between MHT and dementia or mild cognitive impairment. Certainty of the evidence is low.
• Neither change makes hormone therapy a dementia-prevention tool. Decisions still rest on symptoms, age, time since menopause and personal risk.

Why this matters now

For over two decades, the 2002 Women’s Health Initiative (WHI) results shaped how women and doctors thought about hormone therapy. Many women stopped treatment, and many symptomatic women were never offered it. Later analyses showed that age and time since menopause change the risk picture, and that the original headline numbers were often read too broadly. The 2026 label revision is the regulatory catch-up to that long scientific re-reading.

What changed on the label

The FDA began a literature review in November 2025. On 12 February 2026 it announced approved label revisions for six products across four categories: systemic estrogen plus progestogen, systemic estrogen alone, systemic progestogen for women with a uterus who use estrogen, and vaginal estrogen. Risk statements on cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning. Twenty-nine companies have submitted proposed revisions at the agency’s request, so more labels are expected.

Some clinicians urged caution. One menopause specialist quoted in trade press noted that thromboembolism is not discussed in the combination label and questioned the stroke wording for estrogen-alone products. I could not confirm from the sources I read exactly which warnings remain boxed (for example, endometrial cancer with unopposed estrogen), so check the current label for any product you prescribe or use.

What the dementia meta-analysis found

Melville, He and Desai searched four databases for studies from 2000 to October 2025. They pooled one randomized trial and nine observational studies, with 1,016,055 participants. Across subgroups by timing, duration and type of therapy, they reported no significant association with dementia or mild cognitive impairment. The authors conclude that hormone therapy does not appear to raise or lower dementia risk, so dementia should not drive the decision either way.

Two cautions. First, the evidence is thin where it matters most: few randomized trials, and mostly low-certainty observational data prone to confounding. Second, the review found no eligible data on early menopause, premature ovarian insufficiency or established mild cognitive impairment. Absence of a signal is not proof of safety in those groups.

For clinicians

• Dementia review: Melville M, He L, Desai R. Systematic review and meta-analysis; Embase, MEDLINE, PsycINFO, Cochrane; 1 Jan 2000 to 25 Oct 2025; 10 studies (1 RCT, 9 observational); n = 1,016,055. Prepared to inform WHO guidance on cognitive decline and dementia expected in 2026.
• Effect sizes: I did not obtain the full text. Secondary summaries disagree on some pooled estimates, and one reports a hazard ratio above 1 for combined therapy in women 65 and older (from a single RCT) alongside a conclusion of no significant effect. Verify the point estimates and confidence intervals in the paper before citing numbers.
• Limitations: Low or very low certainty for most outcomes, few RCTs, confounding in cohorts, heterogeneity in formulation, route and timing, no data on premature ovarian insufficiency.
• Label change: Six products in the first FDA batch; transdermal estradiol was reportedly not included. Label text, not press coverage, should guide prescribing.
• Background: WHI findings (Rossouw 2002; Manson 2013) remain the main randomized evidence on cardiovascular and breast outcomes, with age and time-since-menopause stratification central to interpretation.

What’s new in regulation

FDA (US). Beyond the hormone labels, on 6 January 2026 the FDA updated its General Wellness guidance. Law-firm summaries say non-invasive wearables may display physiologic values, trends and baselines in wellness contexts such as sleep, stress and recovery if the values are validated, but may not name diseases, call outputs abnormal or diagnostic, or give clinical thresholds. What counts as adequate validation remains unclear. CE/EU. I did not verify any new CE-marking, MDR or IVDR development specific to hormone monitoring this cycle, so none is claimed here.

What this means for patients

• If hot flashes, night sweats, sleep disruption or vaginal symptoms are hurting your quality of life, hormone therapy remains a legitimate topic to raise. A softer label does not mean zero risk.
• Do not start or continue hormone therapy to prevent dementia. The best current evidence does not support that.
• Bring your own history: age, years since your last period, clotting, migraine with aura, breast and uterine history, family history.
• Ask for a plan with a start date, a review date and a clear goal.
• Symptom diaries, sleep data and resting heart rate or HRV trends can make appointments more productive. They are conversation starters, not diagnoses.

6Letters is building non-invasive, wearable-based hormone insight tools, including MOJO QUEEN for women, which is not yet launched. Learn more at 6letters.co.kr.

References

1. Melville M, He L, Desai R. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025;6(12):100803. doi:10.1016/j.lanhl.2025.100803 (DOI as reported by secondary sources; confirm). Press release: https://www.ucl.ac.uk/news/2025/dec/menopause-hormone-therapy-does-not-appear-impact-dementia-risk (23 Dec 2025).
2. FDA approves labeling changes to menopausal hormone therapy products (news release, 12 Feb 2026). Coverage: https://www.patientcareonline.com/view/fda-removes-boxed-warnings-cardiovascular-cancer-dementia-risks-from-select-menopausal-hormone-therapy-labels and https://www.healio.com/news/endocrinology/20260316/fda-approves-revised-hormone-therapy-black-box-warning-for-menopause-treatments
3. Greenberg Traurig. FDA updates two digital health final guidance documents (Jan 2026). https://www.gtlaw.com/en/insights/2026/1/fda-updates-two-digital-health-final-guidance-documents
4. Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321
5. Manson JE et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040